Need professional-grade analysis? Visit stockanalysis.com
$9.56B
N/A
67
N/A
Price Chart
Risk-Adjusted Performance
Also Listed On
ABIVAX Société Anonyme (AAVXF) Price Performance
ABIVAX Société Anonyme (AAVXF) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $115.65.
Over the past year, AAVXF has traded between a low of $5.81 and a high of $133.00. The stock has gained 1573.7% over this period. It is currently 13.0% below its 52-week high.
ABIVAX Société Anonyme has a market capitalization of $9.56B.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $5.31M
- EBITDA
- $-217,952,992
- Profit Margin
- -1633.08%
- EPS (TTM)
- -5.12
- Book Value
- 7.53
Technical Indicators
- 52 Week High
- $133.40
- 52 Week Low
- $5.81
- 50 Day MA
- $122.36
- 200 Day MA
- $84.05
- Beta
- -0.38
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- 1799.27
- Price/Book
- 15.50
- Enterprise Value
- $8.59B